According to the results of open, controlled, retro prospective, comparative, randomized clinical trial found an increase in the efficacy of the combined treatment of malignant brain tumors in the application of intraoperative local chemotherapy drug (LHT) temodex. In particular, the median survival of patients with Grade III–IV tumors in the supratentorial localization background intraoperative LHT increased when radical resection of the tumor with 11.15 months to 78.6 19.65 months. When subtotal resection of this figure increased to 9.025 months to 17.23 months, with convexital dissemination process – from 10.0 months to 19.65 months, and on the paraventricular location – from 8.35 months to 14.775 months, respectively. It is shown that when comparing the patients in the control group and the main aged 40 to 60 years, with Grade III–IV tumors, median survival increased from 10.45 months to 16.25 months. Disease-free patients and control group with Grade II–IV tumors were found to be 17.25 months and 8.75 months respectively.
Authors: D.P. Veevnik, A.S. Fedulov, T.L. Yurkshtovich
Keywords: primary neuroepithelial brain tumors, intraoperative local chemotherapy, temozolomide, temodeks, survival, disease-free.
Contact information
Full Company Name:
Double Bond Pharmaceutical International AB (publ)
Corporate identity:
556991-6082
Stock short name:
DBP B
Share ISIN code:
SE0007185525
For more info, contact
Igor Lokot, CEO
Homepage:
E-mail:
Blog:
Follow us on:
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.